rs34529039

Variant summary

Our verdict is Benign. The variant received -21 ACMG points: 0P and 21B. BP4_StrongBP6_Very_StrongBP7BA1

The NM_004364.5(CEBPA):​c.690G>T​(p.Thr230Thr) variant causes a synonymous change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.14 in 1,149,514 control chromosomes in the GnomAD database, including 12,241 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★★).

Frequency

Genomes: 𝑓 0.16 ( 2221 hom., cov: 32)
Exomes 𝑓: 0.14 ( 10020 hom. )

Consequence

CEBPA
NM_004364.5 synonymous

Scores

2

Clinical Significance

Benign criteria provided, multiple submitters, no conflicts B:7

Conservation

PhyloP100: -0.0510

Publications

18 publications found
Variant links:
Genes affected
CEBPA (HGNC:1833): (CCAAT enhancer binding protein alpha) This intronless gene encodes a transcription factor that contains a basic leucine zipper (bZIP) domain and recognizes the CCAAT motif in the promoters of target genes. The encoded protein functions in homodimers and also heterodimers with CCAAT/enhancer-binding proteins beta and gamma. Activity of this protein can modulate the expression of genes involved in cell cycle regulation as well as in body weight homeostasis. Mutation of this gene is associated with acute myeloid leukemia. The use of alternative in-frame non-AUG (GUG) and AUG start codons results in protein isoforms with different lengths. Differential translation initiation is mediated by an out-of-frame, upstream open reading frame which is located between the GUG and the first AUG start codons. [provided by RefSeq, Dec 2013]
CEBPA-DT (HGNC:25710): (CEBPA divergent transcript)

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -21 ACMG points.

BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.53).
BP6
Variant 19-33301725-C-A is Benign according to our data. Variant chr19-33301725-C-A is described in ClinVar as Benign. ClinVar VariationId is 21402.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BP7
Synonymous conserved (PhyloP=-0.051 with no splicing effect.
BA1
GnomAd4 highest subpopulation (AFR) allele frequency at 95% confidence interval = 0.249 is higher than 0.05.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
CEBPANM_004364.5 linkc.690G>T p.Thr230Thr synonymous_variant Exon 1 of 1 ENST00000498907.3 NP_004355.2 P49715-1
CEBPANM_001287424.2 linkc.795G>T p.Thr265Thr synonymous_variant Exon 1 of 1 NP_001274353.1 P49715-4
CEBPANM_001287435.2 linkc.648G>T p.Thr216Thr synonymous_variant Exon 1 of 1 NP_001274364.1 P49715-2
CEBPANM_001285829.2 linkc.333G>T p.Thr111Thr synonymous_variant Exon 1 of 1 NP_001272758.1 P49715-3

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
CEBPAENST00000498907.3 linkc.690G>T p.Thr230Thr synonymous_variant Exon 1 of 1 6 NM_004364.5 ENSP00000427514.1 P49715-1
ENSG00000267727ENST00000587312.1 linkn.357-90C>A intron_variant Intron 1 of 1 3
CEBPA-DTENST00000718467.1 linkn.-29C>A upstream_gene_variant

Frequencies

GnomAD3 genomes
AF:
0.158
AC:
23314
AN:
147742
Hom.:
2208
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.253
Gnomad AMI
AF:
0.0996
Gnomad AMR
AF:
0.117
Gnomad ASJ
AF:
0.132
Gnomad EAS
AF:
0.0100
Gnomad SAS
AF:
0.0822
Gnomad FIN
AF:
0.0963
Gnomad MID
AF:
0.152
Gnomad NFE
AF:
0.136
Gnomad OTH
AF:
0.155
GnomAD2 exomes
AF:
0.186
AC:
255
AN:
1372
AF XY:
0.203
show subpopulations
Gnomad AFR exome
AF:
0.357
Gnomad AMR exome
AF:
0.00
Gnomad ASJ exome
AF:
0.100
Gnomad FIN exome
AF:
0.149
Gnomad NFE exome
AF:
0.196
Gnomad OTH exome
AF:
0.176
GnomAD4 exome
AF:
0.138
AC:
138024
AN:
1001664
Hom.:
10020
Cov.:
28
AF XY:
0.137
AC XY:
65049
AN XY:
473778
show subpopulations
African (AFR)
AF:
0.267
AC:
5334
AN:
19994
American (AMR)
AF:
0.111
AC:
640
AN:
5746
Ashkenazi Jewish (ASJ)
AF:
0.136
AC:
1423
AN:
10492
East Asian (EAS)
AF:
0.0148
AC:
268
AN:
18130
South Asian (SAS)
AF:
0.0864
AC:
1667
AN:
19302
European-Finnish (FIN)
AF:
0.104
AC:
1744
AN:
16750
Middle Eastern (MID)
AF:
0.178
AC:
477
AN:
2680
European-Non Finnish (NFE)
AF:
0.139
AC:
121381
AN:
871034
Other (OTH)
AF:
0.136
AC:
5090
AN:
37536
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.526
Heterozygous variant carriers
0
5715
11430
17145
22860
28575
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
5228
10456
15684
20912
26140
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.158
AC:
23353
AN:
147850
Hom.:
2221
Cov.:
32
AF XY:
0.154
AC XY:
11068
AN XY:
72048
show subpopulations
African (AFR)
AF:
0.253
AC:
10351
AN:
40910
American (AMR)
AF:
0.117
AC:
1739
AN:
14918
Ashkenazi Jewish (ASJ)
AF:
0.132
AC:
448
AN:
3402
East Asian (EAS)
AF:
0.00987
AC:
50
AN:
5068
South Asian (SAS)
AF:
0.0831
AC:
398
AN:
4790
European-Finnish (FIN)
AF:
0.0963
AC:
871
AN:
9040
Middle Eastern (MID)
AF:
0.155
AC:
45
AN:
290
European-Non Finnish (NFE)
AF:
0.136
AC:
9047
AN:
66472
Other (OTH)
AF:
0.153
AC:
314
AN:
2056
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.495
Heterozygous variant carriers
0
957
1914
2870
3827
4784
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
246
492
738
984
1230
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.144
Hom.:
231
Bravo
AF:
0.160

ClinVar

Significance: Benign
Submissions summary: Benign:7
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

not provided Benign:3
Nov 27, 2024
ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Sep 14, 2018
GeneDx
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

-
Breakthrough Genomics, Breakthrough Genomics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:not provided

- -

Acute myeloid leukemia Benign:2
Feb 04, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Dec 19, 2024
Genomic Medicine Center of Excellence, King Faisal Specialist Hospital and Research Centre
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

not specified Benign:1
-
PreventionGenetics, part of Exact Sciences
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Inborn genetic diseases Benign:1
Oct 18, 2024
Ambry Genetics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
-0.53
CADD
Benign
9.3
DANN
Benign
0.79
PhyloP100
-0.051
Mutation Taster
=100/0
polymorphism (auto)

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs34529039; hg19: chr19-33792631; COSMIC: COSV57196771; COSMIC: COSV57196771; API